The Dopamine Receptors

ISBN-13: 9781617796562 / Angielski / Miękka / 2012 / 648 str.

Kim A. Neve

Opis

As sites of action for drugs used to treat schizophrenia and Parkinson's disease, dopamine receptors are among the most validated drug targets for neuropsychiatric disorders. Dopamine receptors are also drug targets or potential targets for other disorders such as substance abuse, depression, Tourette's syndrome, and attention deficit hyperactivity disorder. Updated from the successful first edition, "The Dopamine Receptors" serves as a reference work on dopamine receptors while also highlighting the areas of research that are most active today. To achieve this goal, authors have written chapters that set a broad area of research in its historical context, rather than focusing on the research output of their own laboratories.

Recenzje

...extremely well-written and thoroughly referenced... All neuroscientists searching for an invaluable reference which provides a clearer understanding of the dopamine field and its future direction should have this book at their fingertips. -Journal of Medicinal Chemistry

Spis treści

Table of Contents Preface Historical Overview: Introduction to the Dopamine Receptors Philip Seeman Gene and Promoter Structures of the Dopamine Receptors Ursula M. D’Souza Structural Basis of Dopamine Receptor Activation Irina S. Moreira, Lei Shi, Zachary Freyberg, Spencer S. Eriksen, Harel Weinstein, and Johnathan A. Javitch Dopamine Receptor Subtype-Selective Drugs: D1-like Receptors David E. Nichols Dopamine Receptor Subtype-Selective Drugs: D2-like Receptors Olaf Prante, Miriam Dörfler, and Peter Gmeiner Dopamine Receptor Signaling: Intracellular Pathways to Behavior Robert J. Romanelli, John T. Williams, and Kim A. Neve Dopaminergic Modulation of Glutamatergic Signaling in Striatal Medium Spiny Neurons Weixing Shen and D. James Surmeier Regulation of Dopamine Receptor Trafficking and Responsiveness Melissa L. Perreault, Vaneeta Verma, Brian F. O’Dowd and Susan R. George Dopamine Receptor-Interacting Proteins Lisa A. Hazelwood, R. Benjamin Free, and David R. Sibley Dopamine Receptor Oligomerization Kjell Fuxe, Daniel Marcellino, Diego Guidolin, Amina Woods and Luigi Agnati Dopamine Receptor Modulation of Glutamatergic Neurotransmission Carlos Cepeda, Véronique M. André, Emily L. Jocoy and Michael S. Levine Unraveling the Role of Dopamine Receptors in vivo: Lessons from Knockout Mice Emanuele Tirotta, Claudia De Mei, Chisato Iitaka, Maria Ramos, Dawn Holmes, and Emiliana Borrelli Dopamine Receptors and Behavior: From Psychopharmacology to Mutant Models Gerard J. O’Sullivan, Colm O’Tuathaigh, Katsunori Tomiyama, Noriaki Koshikawa, and John L. Waddington Dopamine Modulation of the Prefrontal Cortex and Cognitive Function Jeremy K. Seamans and Trevor W. Robbins In VivoImaging of Dopamine Receptors Anissa Abi-Dargham and Marc Laruelle Dopamine Receptors and the Treatment of Schizophrenia Nathalie Ginovart and Shitij Kapur Dopamine Receptor Subtypes in Reward and Relapse David W. Self Dopamine Receptors and the Treatment of Parkinson’s Disease Eugenia V. Gurevich and Vsevolod V. Gurevich Dopamine Receptor Genetics in Neuropsychiatric Disorders Frankie H. F. Lee and Albert H. C. Wong

Blurb

Dopamine receptors are among the most validated drug targets for neuropsychiatric disorders such as schizophrenia and Parkinson’s disease, and are potential targets for other disorders such as substance abuse, depression, Tourette’s syndrome, and attention deficit hyperactivity disorder. The new knowledge brought from the creation and characterization of mice deficient in each of the subtypes and the development of increasingly subtype-selective agonists and antagonists has fueled many of the chapters new to this second edition, with the use of knock-out mice and subtype-selective drugs meriting discussion in stand-alone chapters. The field of G protein-coupled receptors has also advanced significantly since the first edition, with a model of GPCR signaling based on linear, compartmentalized pathways having been replaced by a more complex, richer model in which neurotransmitter effects are mediated by a signalplex composed of numerous signaling proteins, including multiple GPCRs, other types of receptors, such as ionotropic receptors, accessory and scaffolding proteins, and effectors. This second edition of Dopamine Receptors will be of interest to neurobiologists, pharmacologists and molecular biologists who study the brain, as well as neurologists working on psychiatric diseases.